8FEZ
Prefusion-stabilized SARS-CoV-2 spike protein
Summary for 8FEZ
| Entry DOI | 10.2210/pdb8fez/pdb |
| EMDB information | 29035 |
| Descriptor | Spike glycoprotein (1 entity in total) |
| Functional Keywords | fusion protein, prefusion state, viral protein |
| Biological source | Severe acute respiratory syndrome coronavirus 2 (2019-nCoV, SARS-CoV-2) |
| Total number of polymer chains | 3 |
| Total formula weight | 413975.39 |
| Authors | Gonzalez, K.J.,Mousa, J.J.,Strauch, E.M. (deposition date: 2022-12-07, release date: 2023-04-12, Last modification date: 2024-11-06) |
| Primary citation | Gonzalez, K.J.,Huang, J.,Criado, M.F.,Banerjee, A.,Tompkins, S.M.,Mousa, J.J.,Strauch, E.M. A general computational design strategy for stabilizing viral class I fusion proteins. Nat Commun, 15:1335-1335, 2024 Cited by PubMed Abstract: Many pathogenic viruses rely on class I fusion proteins to fuse their viral membrane with the host cell membrane. To drive the fusion process, class I fusion proteins undergo an irreversible conformational change from a metastable prefusion state to an energetically more stable postfusion state. Mounting evidence underscores that antibodies targeting the prefusion conformation are the most potent, making it a compelling vaccine candidate. Here, we establish a computational design protocol that stabilizes the prefusion state while destabilizing the postfusion conformation. With this protocol, we stabilize the fusion proteins of the RSV, hMPV, and SARS-CoV-2 viruses, testing fewer than a handful of designs. The solved structures of these designed proteins from all three viruses evidence the atomic accuracy of our approach. Furthermore, the humoral response of the redesigned RSV F protein compares to that of the recently approved vaccine in a mouse model. While the parallel design of two conformations allows the identification of energetically sub-optimal positions for one conformation, our protocol also reveals diverse molecular strategies for stabilization. Given the clinical significance of viruses using class I fusion proteins, our algorithm can substantially contribute to vaccine development by reducing the time and resources needed to optimize these immunogens. PubMed: 38351001DOI: 10.1038/s41467-024-45480-z PDB entries with the same primary citation |
| Experimental method | ELECTRON MICROSCOPY (3.72 Å) |
Structure validation
Download full validation report
